Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy

Mohammad Alghounaim 1, Zainab Alsaffar 2, Abdulla Alfraij 2, Saadoun Bin-Hasan 2 3, Entesar Hussain 4

Affiliations

01 January 2022

-

doi: 10.1159/000525468

Abstract

Pertussis is a common respiratory infection caused by the bacterium Bordetella pertussis. Although most cases occur in developing countries, it is considered endemic globally. The World Health Organization estimates there are 20-40 million cases of pertussis annually. Pertussis vaccines played a pivotal role in reducing the burden of pertussis disease as well as infant morbidity and mortality. Although the two forms of pertussis vaccine are effective, each has its advantages and drawbacks. This review aims to review the current knowledge on pertussis vaccines, emphasizing vaccine effectiveness in different populations within a community. Clinical trials have shown favorable vaccine efficacy with acellular pertussis (aP)vaccine. However, observational and population-level studies showed that introducing at least a single dose of whole-cell pertussis (wP) vaccine within the routine immunization schedule is associated with better disease protection and a longer duration of immunity. On the other hand, wP vaccine is more reactogenic and associated with higher adverse events. Therefore, the selection of vaccine should be weighed against the effectiveness, reactogenicity, and cost-effectiveness. Due to its safety profile, aP vaccine can be offered to wider population groups. Booster adolescent and pregnant immunization programs have been implemented globally to control outbreaks and protect vulnerable infants. Due to the variable effectiveness performance of both vaccines, different countries adopted distinctive immunization programs. Determining the right vaccination approach depends on financial consideration, immunization program infrastructure, adverse event monitoring, and pertussis surveillance in the community.

Keywords: Acellular pertussis; Efficacy; Pertussis; Vaccine; Whole-cell.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Similar articles

Acellular vaccines for preventing whooping cough in children.

Zhang L, Prietsch SO, Axelsson I, Halperin SA.Cochrane Database Syst Rev. 2014 Sep 17;2014(9):CD001478. doi: 10.1002/14651858.CD001478.pub6.PMID: 25228233 Free PMC article. Review.

Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update.

Forsyth KD, Tan T, von König CW, Heininger U, Chitkara AJ, Plotkin S.Vaccine. 2018 Nov 19;36(48):7270-7275. doi: 10.1016/j.vaccine.2018.10.028. Epub 2018 Oct 15.PMID: 30337176 Review.

Acellular vaccines for preventing whooping cough in children.

Zhang L, Prietsch SO, Axelsson I, Halperin SA.Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001478. doi: 10.1002/14651858.CD001478.pub5.PMID: 22419280 Updated. Review.

Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.

Matheson AJ, Goa KL.Paediatr Drugs. 2000 Mar-Apr;2(2):139-59. doi: 10.2165/00148581-200002020-00007.PMID: 10937466 Review.

Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.

Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, Van Damme P, Thiriard A, Raze D, Locht C, Poovorawan Y, Leuridan E.Clin Infect Dis. 2020 Jun 24;71(1):72-80. doi: 10.1093/cid/ciz778.PMID: 31418814 Clinical Trial.

Cited by

Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.

Kumar P, Bird C, Holland D, Joshi SB, Volkin DB.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28.PMID: 36576132 Free PMC article. Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep. 2018;67((2)):1–44. - PMC - PubMed
  2.  
    1. Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev Vaccines. 2005;4((2)):173–84. - PubMed
  3.  
    1. WHO vaccine-preventable diseases: monitoring system. 2020. Available from https://apps.who.int/immunization_monitoring/globalsummary/incidences?c=KWT.
  4.  
    1. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39((12)):4396–403. - PMC - PubMed
  5.  
    1. Cherry JD. Epidemic pertussis in 2012 − the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367((9)):785–7. - PubMed
  6.  
    1. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24((5 Suppl)):S10–8. - PubMed
  7.  
    1. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32((12)):1691–7. - PubMed
  8.  
    1. Edwards KM, Decker MD, Halsey NA, Koblin BA, Townsend T, Auerbach B, et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics. 1991;88((5)):1019–23. - PubMed
  9.  
    1. Steinhoff MC, Reed GF, Decker MD, Edwards KM, Englund JA, Pichichero ME, et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics. 1995;96((3)):567–70. - PubMed
  10.  
    1. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6((4)):348–57. - PMC - PubMed
  11.  
    1. Bentsi-Enchill AD, Halperin SA, Scott J, MacIsaac K, Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine. 1997;15((3)):301–6. - PubMed
  12.  
    1. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96((3 Pt 2)):557–66. - PubMed
  13.  
    1. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J. 1997;16((4)):S90–6. - PubMed
  14.  
    1. Aoyama T, Murase Y, Gonda T, Iwata T. Type-specific efficacy of acellular pertussis vaccine. Am J Dis Child. 1988;142((1)):40–2. - PubMed
  15.  
    1. Centers for Disease Control and Prevention From the centers for disease control and prevention. Pertussis − United States, 1997–2000. JAMA. 2002;287((4)):977–9. - PubMed
  16.  
    1. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190((2)):335–40. - PubMed
  17.  
    1. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis caccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012;54((12)):1730–5. - PubMed
  18.  
    1. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012;5((5)):485–500. - PubMed
  19.  
    1. Blumberg DA, Mink CM, Cherry JD, Johnson C, Garber R, Plotkin SA, et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. J Pediatr. 1991;119((2)):194–204. - PubMed
  20.  
    1. Vickers D, Ross AG, Mainar-Jaime RC, Neudorf C, Shah S. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ. 2006;175((10)):1213–7. - PMC - PubMed
  21.  
    1. Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child. 1991;145((11)):1285–9. - PubMed
  22.  
    1. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997;15((15)):1606–12. - PubMed
  23.  
    1. Fulton TR, Phadke VK, Orenstein WA, Hinman AR, Johnson WD, Omer SB. Protective effect of contemporary pertussis vaccines: a systematic review and meta-analysis. Clin Infect Dis. 2016;62((9)):1100–10. - PMC - PubMed
  24.  
    1. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139((5)):e20164091. - PubMed
  25.  
    1. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131((6)):e1716–22. - PubMed
  26.  
    1. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013;56((9)):1248–54. - PubMed
  27.  
    1. Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185((10)):1448–53. - PubMed
  28.  
    1. Podda A, Bona G, Canciani G, Pistilli AM, Contu B, Furlan R, et al. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. J Pediatr. 1995;127((2)):238–43. - PubMed
  29.  
    1. Smits K, Pottier G, Smet J, Dirix V, Vermeulen F, De Schutter I, et al. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Vaccine. 2013;32((1)):111–8. - PubMed
  30.  
    1. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111((2)):787–92. - PMC - PubMed
  31.  
    1. Gill C, Rohani P, Thea DM. The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis. F1000Res. 2017;6:1568. - PMC - PubMed
  32.  
    1. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 2015;13:146. - PMC - PubMed
  33.  
    1. Safarchi A, Octavia S, Luu LD, Tay CY, Sintchenko V, Wood N, et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine. 2015;33((46)):6277–81. - PubMed
  34.  
    1. Dorji D, Mooi F, Yantorno O, Deora R, Graham RM, Mukkur TK. Bordetella pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. Med Microbiol Immunol. 2018;207((1)):3–26. - PubMed
  35.  
    1. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 2013;9((4)):e1003264. - PMC - PubMed
  36.  
    1. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis. 2001;33((Suppl 4)):S288–91. - PubMed
  37.  
    1. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR, Pentacel Study G. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009;123((1)):301–12. - PubMed
  38.  
    1. Wilk MM, Borkner L, Misiak A, Curham L, Allen AC, Mills KHG. Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis. Emerg Microbes Infect. 2019;8((1)):169–85. - PMC - PubMed
  39.  
    1. Wilk MM, Mills KHG. CD4 TRM cells following infection and immunization: implications for more effective vaccine design. Front Immunol. 2018;9:1860. - PMC - PubMed
  40.  
    1. Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol. 2018;11((6)):1763–76. - PubMed
  41.  
    1. Schwartz KL, Kwong JC, Deeks SL, Campitelli MA, Jamieson FB, Marchand-Austin A, et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ. 2016;188((16)):E399–406. - PMC - PubMed
  42.  
    1. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis. 2004;190((3)):535–44. - PubMed
  43.  
    1. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J. 2009;28((2)):152–3. - PubMed
  44.  
    1. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23((29)):3829–35. - PubMed
  45.  
    1. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367((11)):1012–9. - PubMed
  46.  
    1. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308((5)):454–6. - PubMed
  47.  
    1. Immunization Data. World Health Organization; Available from https://immunizationdata.who.int/listing.html?topic=&location=
  48.  
    1. Chitkara AJ, Pujadas Ferrer M, Forsyth K, Guiso N, Heininger U, Hozbor DF, et al. Pertussis vaccination in mixed markets: recommendations from the global pertussis initiative. Int J Infect Dis. 2020;96:482–8. - PubMed
  49.  
    1. Narchi H, Osman W, George JA, Almekhaini LA, Souid AK, Alsuwaidi AR. Pertussis seronegativity in pregnant women in the city of Al Ain, United Arab Emirates. Int J Infect Dis. 2019;89:96–101. - PubMed
  50.  
    1. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014;311((17)):1760–9. - PMC - PubMed
  51.  
    1. Halperin SA, Langley JM, Ye L, MacKinnon-Cameron D, Elsherif M, Allen VM, et al. A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response. Clin Infect Dis. 2018;67((7)):1063–71. - PubMed
  52.  
    1. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014;9:CD001478. - PubMed
  53.  
    1. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14((3)):196–8. - PubMed
  54.  
    1. Rennels MB, Black S, Woo EJ, Campbell S, Edwards KM. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr Infect Dis J. 2008;27((5)):464–5. - PubMed
  55.  
    1. Tormans G, Van Doorslaer E, van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatr. 1998;157((5)):395–401. - PubMed
  56.  
    1. Hawken S, Manuel DG, Deeks SL, Kwong JC, Crowcroft NS, Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am J Epidemiol. 2012;176((11)):1035–42. - PubMed
  57.  
    1. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007;32((3)):186–93. - PubMed
  58.  
    1. Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine. 2004;22((31–32)):4215–27. - PubMed
  59.  
    1. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004;39((1)):20–8. - PubMed
  60.  
    1. Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP. Cost-effectiveness of pertussis vaccination during pregnancy in the United States. Am J Epidemiol. 2016;183((12)):1159–70. - PMC - PubMed
  61.  
    1. Berstad AKH, Holst J, Frøholm LO, Haugen IL, Wedege E, Oftung F, et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol. 2000;49((2)):157–63. - PubMed
  62.  
    1. Berstad AK, Oftung F, Korsvold GE, Haugen IL, Froholm LO, Holst J, et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine. 2000;18((22)):2323–30. - PubMed
  63.  
    1. Baumann E, Binder BR, Falk W, Huber EG, Kurz R, Rosanelli K. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Dev Biol Stand. 1985;61:511–6. - PubMed
  64.  
    1. Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, et al. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis. 2020;20((11)):1290–301. - PubMed
  65.  
    1. Gaillard ME, Bottero D, Errea A, Ormazábal M, Zurita ME, Moreno G, et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine. 2014;32((8)):931–7. - PubMed
  66.  
    1. Zurita ME, Wilk MM, Carriquiriborde F, Bartel E, Moreno G, Misiak A, et al. A pertussis outer membrane vesicle-based vaccine induces lung-resident memory CD4 T cells and protection against bordetella pertussis, including pertactin deficient strains. Front Cell Infect Microbiol. 2019;9:125. - PMC - PubMed
  67.  
    1. Barman S, Soni D, Brook B, Nanishi E, Dowling DJ. Precision vaccine development: cues from natural immunity. Front Immunol. 2021;12:662218. - PMC - PubMed
  68.  
    1. Chasaide CN, Mills KHG. Next-generation pertussis vaccines based on the induction of protective T cells in the respiratory tract. Vaccines. 2020;8((4)):621. - PMC - PubMed
  69.  
    1. Misiak A, Leuzzi R, Allen AC, Galletti B, Baudner BC, D'Oro U, et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine. 2017;35((39)):5256–63. - PubMed
  70.  
    1. Dowling DJ, Smith AJ, Borriello F, Brightman S, Schüller S, Bazin H, et al. Age-specific TLR7/8 adjuvant formulation overcomes hyporesponsiveness to neonatal acellular pertussis vaccination in a mouse model. J Immunol. 2018;200((1 Suppl)):18024–4.
  71.  
    1. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334((6)):349–55. - PubMed
  72.  
    1. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med. 1996;334((6)):341–8. - PubMed
  73.  
    1. Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, uberall M, Laussucq S, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998;101((1 Pt 1)):1–11. - PubMed
  74.  
    1. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 1997;350((9091)):1569–77. - PubMed
  75.  
    1. Heininger U, Cherry JD, Stehr K, Schmitt-Grohé S, Uberall M, Laussucq S, et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics. 1998;102((3 Pt 1)):546–53. - PubMed
  76.  
    1. Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, et al. Impact of the US maternal tetanus, diphtheria, and acellular pertussis vaccination program on preventing pertussis in infants. Clin Infect Dis. 2017;65((12)):1977–83. - PMC - PubMed
  77.  
    1. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infect Dis. 2015;60((3)):333–7. - PubMed
  78.  
    1. Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017;64((1)):3–8. - PubMed
  79.  
    1. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384((9953)):1521–8. - PubMed
  80.  
    1. Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, et al. A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine. N Engl J Med. 1995;333((16)):1045–1050. - PubMed

Page Navigation